


The invention concerns 3-substituted 3,4,5,6,7,8-hexahydro-pyrido[4,3':4,5]thieno-[2,3-d]pyrimidine derivatives of formula (I) in which: R<sup>1</sup> designates a hydrogen atom, a C<sub>1</sub>-C<sub>4</sub> alkyl group, an acetyl or benzoyl group, a phenylalkyl C<sub>1</sub>-C<sub>4</sub> group - the aromatic optionally being substituted by halogen, C<sub>1</sub>-C<sub>4</sub> alkyl, trifluoromethyl, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, amino, cyano or nitro groups - a naphthylalkyl C<sub>1</sub>-C<sub>3</sub> group, a phenylalkanone C<sub>2</sub>-C<sub>3</sub> group or a phenylcarbamoylalkyl C<sub>2</sub> group, wherein the phenyl group can be substituted by halogen; R<sup>2</sup> designates a phenyl, pyridyl, pyrimidinyl or pyrazinyl group which can optionally be mono-, di- or tri-substituted by halogen atoms, C<sub>1</sub>-C<sub>4</sub> alkyl, trifluoromethyl, trifluoromethoxy, hydroxy, C<sub>1</sub>-C<sub>4</sub> alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups and can optionally be anellated with a benzene nucleus, which can optionally be mono- or di-substituted by halogen atoms, C<sub>1</sub>-C<sub>4</sub> alkyl, hydroxy, trifluoromethyl, C<sub>1</sub>-C<sub>4</sub> alkoxy, amino, cyano or nitro groups and can optionally contain 1 nitrogen atom, or with a 5- or 6-member ring which can contain between 1 and 2 oxygen atoms, or can be substituted by a phenyl-C<sub>1</sub>-C<sub>2</sub> alkyl or alkoxy group, wherein the phenyl group can be substituted by halogen, a methyl, trifluoromethyl or methoxy group; A designates NH or an oxygen atom; B designates hydrogen or methyl; C designates hydrogen, methyl or hydroxy; X designates a nitrogen atom; Y is CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub> or CH<sub>2</sub>-CH; Z designates a nitrogen atom, a carbon atom or CH, wherein the bond between Y and Z can also be a double bond; and n is the number 2, 3 or 4, and their physiologically compatible salts. These compounds are suitable as medicaments for treating diseases in which the serotonin concentration is reduced and in which the activity of the presynaptic receptors 5-HT<sub>1B</sub>, 5-HT<sub>1A</sub>, 5HT<sub>1D</sub> is to be blocked within a therapeutic context without greatly influencing other receptors. Such diseases include, for example, depression.



(I)